SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44])

The summary for the SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44]) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44]): Purpose. This Funding Opportunity Announcement (FOA), launched as a pilot initiative at the National Institutes of Health (NIH) by the National Cancer Institute (NCI), solicits Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional NIH funding to support the next stage of development for previously-funded NIH SBIR Phase II projects applicable to cancer therapies and cancer imaging technologies. The purpose of this FOA is to address the funding gap known as the Valley of Death between the end of the SBIR Phase II award and the commercialization stage. This FOA is also designed to promote partnerships between NIH's SBIR Phase II awardees and third-party investors and/or strategic partners to facilitate and accelerate the capital intensive steps that are required to commercialize new products/technologies emerging from NIH-funded SBIR Phase II projects. Applicants responding to this FOA must provide a specific commercialization plan that includes details on any independent third-party investor funding that has already been secured or is anticipated. It is expected that the level of this independent third-party funding will equal or exceed the NCI funds being requested throughout the Phase II Bridge Award project period. NCI support is thus intended to benefit cancer patients by accelerating the development of new cancer therapies (including anticancer agents and oncological therapeutic devices) and imaging devices/technologies toward commercialization. Only applications proposing projects in these areas will be considered responsive. Proposed projects may address preclinical and/or clinical stages of technology development. Clinical trials may be proposed as needed but are not required.
Federal Grant Title: SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR [R44])
Federal Agency Name: National Institutes of Health
Grant Categories: Education Health
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-CA-08-021
Type of Funding: Grant
CFDA Numbers: 93.39493.395
CFDA Descriptions: Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research
Current Application Deadline: No deadline provided
Original Application Deadline: Feb 27, 2009
Posted Date: May 14, 2008
Creation Date: May 14, 2008
Archive Date: Dec 03, 2008
Total Program Funding: $10,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
Small businesses
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV
FBOWebmaster@OD.NIH.GOV If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
More Grants from the National Institutes of Health
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2007-2021 FederalGrants.com